CHINARES PHARMA (03320) Subsidiary China Resources Double-Crane Gets Approval to Issue RMB 3 Billion Corporate Bonds

Stock News

01/26

CHINARES PHARMA (03320) announced that its non-wholly-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd., has received a registration approval notice (No. 118 [2026]) from the China Securities Regulatory Commission for its plan to issue corporate bonds to qualified investors in the People's Republic of China. The notice is valid for 24 months from the date of issuance, during which China Resources Double-Crane may issue corporate bonds in tranches with a total value of RMB 3 billion.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1150835394"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1150835394\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1150835394?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-26 21:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150835394","market":"fut","top_or_hot":-1,"title":"CHINARES PHARMA (03320) Subsidiary China Resources Double-Crane Gets Approval to Issue RMB 3 Billion Corporate Bonds","media":"Stock News","content":"<p>CHINARES PHARMA (03320) announced that its non-wholly-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd., has received a registration approval notice (No. 118 [2026]) from the China Securities Regulatory Commission for its plan to issue corporate bonds to qualified investors in the People's Republic of China.\nThe notice is valid for 24 months from the date of issuance, during which China Resources Double-Crane may issue corporate bonds in tranches with a total value of RMB 3 billion.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CHINARES PHARMA (03320) Subsidiary China Resources Double-Crane Gets Approval to Issue RMB 3 Billion Corporate Bonds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCHINARES PHARMA (03320) Subsidiary China Resources Double-Crane Gets Approval to Issue RMB 3 Billion Corporate Bonds\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-01-26 21:39</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>CHINARES PHARMA (03320) announced that its non-wholly-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd., has received a registration approval notice (No. 118 [2026]) from the China Securities Regulatory Commission for its plan to issue corporate bonds to qualified investors in the People's Republic of China.\nThe notice is valid for 24 months from the date of issuance, during which China Resources Double-Crane may issue corporate bonds in tranches with a total value of RMB 3 billion.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"國家隊","start_time":0,"source_url":"","article_id":"1150835394","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150835394","pubTimestamp":1769434795,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CHINARES PHARMA (03320) announced that its non-wholly-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd., has received a registration approval notice (No. 118 [2026]) from the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600062":"华润双鹤","BK0028":"国家队","BK1570":"华润系","BK0185":"二线龙头","BK0239":"医药制造","BK1191":"制药","BK0188":"融资融券","03320":"华润医药","BK0175":"白马股","BK0010":"央企"},"translate_title":"CHINARES PHARMA(03320)附属华润双鹤获批发行30亿元人民币公司债券","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600062":1,"03320":1},"content_text":"CHINARES PHARMA (03320) announced that its non-wholly-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd., has received a registration approval notice (No. 118 [2026]) from the China Securities Regulatory Commission for its plan to issue corporate bonds to qualified investors in the People's Republic of China.\nThe notice is valid for 24 months from the date of issuance, during which China Resources Double-Crane may issue corporate bonds in tranches with a total value of RMB 3 billion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}